Evaluation of Efficacy and Safety of AHPL/AYCAP/0413 capsule and AHPL/AYTOP/0213 cream in patients suffering from Acne Vulgaris - NI

Ari Healthcare Pvt Ltd0 个研究点目标入组 63 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Subjects suffering from acne vulgaris (mild, moderate and severe) as diagnosed by physician or dermatologist
•2. Subject willing to participate in clinical trial and who have read, understood and signed informed consent form.
•3. Subjects willing to make all required study visits
•4. Subjects willing to follow study instructions given by the investigator

•1.Patients with preexisting systemic disease necessitating long-term medications.
•2.Patients with history of genetic and endocrinal disorders.
•3.Patients having menstrual disorders and patients with drug induced acne.
•4.Patients having systemic/topical treatment for acne vulgaris since last 3 months.
•5.Patients who are using any kind of face application for the management of acne.
•6.Patients suffering from major/severe illness(s).
•7.Patients having or given history of HIV, Hepatitis B or C, diabetes mellitus, hepatic/renal diseases and/or any other major skin disease(s).
•8.Pregnant and lactating women
•9.Subject having known hypersensitivity to any ingredient of investigational drugs .
•10.Subjects with significant abnormal laboratory parameters
•11.ECG demonstrating any signs of uncontrolled arrhythmia

发起方

Ari Healthcare Pvt Ltd